Forum
Warto wiedzieć
Twoje Forum
Forum Giełda
+Dodaj wątek
Opublikowano przy kursie:
16,16 zł
, zmiana od tamtej pory:
-51,92%
Re: Badanie edison group
Zgłoś do moderatoraWg Edisonów:
The return of the development rights to OATD-01 from Galapagos presents a considerable opportunity for Molecure, in our view. Despite a two-year development delay following the 2020 deal with Galapagos, the company has benefited from additional data generated by Galapagos as well as its PLN125m (US$28m) upfront licensing payment. Molecure will now continue to develop OATD-01 in sarcoidosis, an indication with substantial unmet medical need. If a disease-modifying effect is demonstrated, we see potential in other interstitial lung diseases (ILD) such as IPF.
The return of the development rights to OATD-01 from Galapagos presents a considerable opportunity for Molecure, in our view. Despite a two-year development delay following the 2020 deal with Galapagos, the company has benefited from additional data generated by Galapagos as well as its PLN125m (US$28m) upfront licensing payment. Molecure will now continue to develop OATD-01 in sarcoidosis, an indication with substantial unmet medical need. If a disease-modifying effect is demonstrated, we see potential in other interstitial lung diseases (ILD) such as IPF.
- Kurs Euro
- Kurs dolar
- Kurs frank
- Kurs funt
- Wiron
- Przelicznik walut
- Kantor internetowy
- Kalkulator wynagrodzeń
- Umowa zlecenie
- Kredyt na mieszkanie
- Kredyt na samochód
- Kalkulator kredytowy
- Revolut
- Winiety
- Jak grać na giełdzie?
- Jak wziąć kredyt hipoteczny?
- Rejestracja samochodu
- Jak rozwiązać umowę z Orange
- Koszty uzyskania przychodów
- Sesje elixir
- PB weekend
- RRSO co to jest?
- Blogbank.pl
- Promocje bankowe - zgarnijpremie.pl
- Stopa procentowa
